{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:21:56Z","timestamp":1763018516885,"version":"3.44.0"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dutch Sj\u00f6gren\u2019s Patients Association"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate humoral and cellular immune responses and adverse events (AEs) after COVID-19 vaccination in patients with primary Sj\u00f6gren\u2019s syndrome (pSS) compared to healthy controls (HC), and disease activity following vaccination in patients with pSS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>67 patients with pSS and 33 HC (ratio 2:1) received COVID-19 vaccinations following the Dutch vaccination programme. Patients with pSS did not use immunomodulatory drugs, except hydroxychloroquine. Anti-spike 1 receptor binding domain IgG serum antibody levels were measured 28 days after complete vaccination. AEs were collected 7\u2009days after vaccination. In a subgroup, salivary anti-SARS-CoV-2 antibodies and T-cell response by interferon-\u03b3 enzyme-linked immune absorbent spot was measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>47 patients with pSS (70%) and 14 HC (42%) received BNT162b2 (Pfizer-BioNtech), 13 (19%) and 5 (15%) received ChAdOx1 nCoV-19 (AstraZeneca), 6 (9%) and 8 (24%) received mRNA-1273 (Moderna), and 1 (1%) and 6 (18%) received Ad.26.COV2.S (Janssen). All participants had positive anti-SARS-CoV-2 antibody levels (&gt;2500 AU\/mL) postvaccination. No differences in anti-SARS-CoV-2 antibody levels were observed between patients with pSS and HC, for each vaccine type. Salivary anti-SARS-CoV-2 IgG antibodies also increased, and a T-cell response was observed in patients with pSS and HC. Frequencies of systemic AEs were comparable between patients with pSS and HC (first vaccination: 34\/67 (51%) vs 16\/33 (48%), p=0.83; second: 41\/66 (62%) vs 14\/25 (56%), p=0.59). No significant worsening was observed in patient-reported and systemic disease activity, including auto-antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with pSS had similar humoral and cellular immune responses as HC, suggesting COVID-19 vaccination is effective in patients with pSS. AEs were also comparable, and no increase in disease activity was seen in patients with pSS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002265","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:21:08Z","timestamp":1649769668000},"page":"e002265","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity and safety of COVID-19 vaccination in patients with primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1136","volume":"8","author":[{"given":"Gwenny M","family":"Verstappen","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5449","authenticated-orcid":false,"given":"Liseth","family":"de Wolff","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-7640","authenticated-orcid":false,"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hella-Marie","family":"Heiermann","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7382-8322","authenticated-orcid":false,"given":"Yannick","family":"van Sleen","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Visser","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janneke H","family":"Terpstra","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri A","family":"Diavatopoulos","sequence":"additional","affiliation":[{"name":"Radboud Centre for Infectious Diseases, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands"},{"name":"Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"van der Heiden","sequence":"additional","affiliation":[{"name":"Medical Microbiology and Infection Prevention, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan","family":"Vissink","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"van Baarle","sequence":"additional","affiliation":[{"name":"Medical Microbiology and Infection Prevention, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"},{"name":"Centre for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans G M","family":"Kroese","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"2025090312412355000_8.1.e002265.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220059"},{"key":"2025090312412355000_8.1.e002265.2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312412355000_8.1.e002265.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"2025090312412355000_8.1.e002265.4","doi-asserted-by":"crossref","unstructured":"Haberman RH , Herati RS , Simon D . Methotrexate hampers immunogenicity to BNT162B2 mRNA covid-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2020:1339\u201344.","DOI":"10.1136\/annrheumdis-2021-220597"},{"key":"2025090312412355000_8.1.e002265.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00222-8"},{"key":"2025090312412355000_8.1.e002265.6","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.891439"},{"key":"2025090312412355000_8.1.e002265.7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/rheumatology\/kez509","article-title":"Viral antigens elicit augmented immune responses in primary Sj\u00f6gren\u2019s syndrome","volume":"59","author":"Bj\u00f6rk","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312412355000_8.1.e002265.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210509"},{"key":"2025090312412355000_8.1.e002265.9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sj\u00f6gren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312412355000_8.1.e002265.10","first-page":"837","article-title":"Genetic and clinical basis for two distinct subtypes of primary Sj\u00f6gren's syndrome","volume":"60","author":"Thorlacius","year":"2021","journal-title":"Rheumatology"},{"key":"2025090312412355000_8.1.e002265.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren's syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"key":"2025090312412355000_8.1.e002265.12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/sji.12520","article-title":"Expression of Toll-like receptors in peripheral blood mononuclear cells of patients with primary Sj\u00f6gren's syndrome","volume":"85","author":"Karlsen","year":"2017","journal-title":"Scand J Immunol"},{"key":"2025090312412355000_8.1.e002265.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.13719"},{"key":"2025090312412355000_8.1.e002265.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210571"},{"key":"2025090312412355000_8.1.e002265.15","unstructured":"Labonovum, the Netherlands. Available: https:\/\/labonovum.nl\/en\/ [Accessed 24 Dec 2021]."},{"key":"2025090312412355000_8.1.e002265.16","unstructured":"Pharmacovigilance center Lareb, the Netherlands. Available: https:\/\/www.lareb.nl\/news\/bij-vaccinatie-na-corona-vaker-bekende-bijwerkingen [Accessed 24 Dec 2021]."},{"key":"2025090312412355000_8.1.e002265.17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa479"},{"key":"2025090312412355000_8.1.e002265.18","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025090312412355000_8.1.e002265.19","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sj\u00f6gren's syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312412355000_8.1.e002265.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25949-x","article-title":"SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms","volume":"12","author":"Fr\u00f6berg","year":"2021","journal-title":"Nat Commun"},{"key":"2025090312412355000_8.1.e002265.21","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1757"},{"key":"2025090312412355000_8.1.e002265.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102743","article-title":"A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"125","author":"Tzioufas","year":"2021","journal-title":"J Autoimmun"},{"key":"2025090312412355000_8.1.e002265.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220461"},{"key":"2025090312412355000_8.1.e002265.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221097"},{"key":"2025090312412355000_8.1.e002265.25","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312412355000_8.1.e002265.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101505","article-title":"T cell immunity to SARS-CoV-2","volume":"55","author":"Niessl","year":"2021","journal-title":"Semin Immunol"},{"key":"2025090312412355000_8.1.e002265.27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/vaccines9121499","article-title":"Nasal and salivary mucosal humoral immune response elicited by mRNA BNT162b2 COVID-19 vaccine compared to SARS-CoV-2 natural infection","volume":"9","author":"Guerrieri","year":"2021","journal-title":"Vaccines"},{"key":"2025090312412355000_8.1.e002265.28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20411\/pai.v6i1.441","article-title":"Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva","volume":"6","author":"Ketas","year":"2021","journal-title":"Pathog Immun"},{"key":"2025090312412355000_8.1.e002265.29","doi-asserted-by":"crossref","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"key":"2025090312412355000_8.1.e002265.30","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102541","article-title":"Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA","volume":"10","author":"Piano Mortari","year":"2021","journal-title":"Cells"},{"key":"2025090312412355000_8.1.e002265.31","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(21)00181-8","article-title":"Adverse events after first COVID-19 vaccination in patients with autoimmune diseases","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090312412355000_8.1.e002265.32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001814"},{"key":"2025090312412355000_8.1.e002265.33","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR coronavirus vaccine (COVAX) physician-reported registry","author":"Machado","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090312412355000_8.1.e002265.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:41:33Z","timestamp":1756928493000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/rmdopen-2022-002265"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002265","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}